Compare GTLB & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTLB | XOMAP |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | N/A |
| IPO Year | 2021 | N/A |
| Metric | GTLB | XOMAP |
|---|---|---|
| Price | $38.77 | $26.75 |
| Analyst Decision | Buy | |
| Analyst Count | 27 | 0 |
| Target Price | ★ $54.59 | N/A |
| AVG Volume (30 Days) | ★ 5.5M | N/A |
| Earning Date | 12-02-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $906,253,000.00 | N/A |
| Revenue This Year | $26.43 | N/A |
| Revenue Next Year | $20.01 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.36 | N/A |
| 52 Week Low | $35.81 | N/A |
| 52 Week High | $74.18 | N/A |
| Indicator | GTLB | XOMAP |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 56.44 |
| Support Level | $35.81 | $26.50 |
| Resistance Level | $41.55 | $26.85 |
| Average True Range (ATR) | 1.66 | 0.17 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 37.12 | 78.62 |
GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.